Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline. The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy.
Stock Analysts’ new coverage for Tuesday, May 16th: StockNews.com assumed coverage on shares of ATA Creativity Global (NASDAQ:AACG). They issued a sell rating on the stock. StockNews.com began coverage on shares of Atlantic American (NASDAQ:AAME). StockNews.com issued a hold rating on the stock. StockNews.com began coverage on shares of ADDvantage Technologies Group (NASDAQ:AEY). They issued […]
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and Corporate Update Conference Call Cancelled ... | May 15, 2023
ALPHARETTA, Ga. — ALPHARETTA, Ga. — Alimera Sciences Inc. on Monday reported a loss of $5 million in its first quarter. The Alpharetta, Georgia-based company said it had a loss of... | May 15, 2023
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other equities research analysts also recently commented on ALIM. HC Wainwright reissued a buy rating and issued a $9.00 target price on shares of […]